Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343402 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06343402 is a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). The registered enrollment target is 250 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06343402, a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG BBO-8520
Study Locations (20)
California
- University of California - San Diego Moores Cancer Center - La Jolla
- University of California San Francisco - San Francisco
- UCLA Health - Santa Monica Cancer Care - Santa Monica
New York
- Roswell Park Cancer Institute - Buffalo
- Perlmutter Cancer Center - NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- Yale Cancer Center - New Haven
- Norwalk Hospital - Norwalk
Texas
- Oncology Consultants Texas Medical Center - Houston
- USOR - Texas Oncology - (DFW) Waco - Waco
Alabama
- O'Neal Comprehensive Cancer Center at UAB - Birmingham
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- OSF Saint Francis Medical Center - Peoria
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06343402
The ClinicalTrials.gov registry entry for NCT06343402 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The listed sponsor is TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06343402 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06343402 about?
NCT06343402 is a clinical study titled "Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer". A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten r...
What is the current status of trial NCT06343402?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-05-22. Estimated completion is 2028-02.
What conditions does trial NCT06343402 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, Metastatic Non Small Cell Lung Cancer, Metastatic Lung Cancer, Kras G12C.
What interventions are being tested in trial NCT06343402?
The interventions under investigation include: Pembrolizumab (DRUG), BBO-8520 (DRUG).
Who is sponsoring clinical trial NCT06343402?
This trial is sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343402 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.